Short Summary
Mercedes‑Benz and Phelan Group settled their IPR dispute over U.S. Patent 10,259,465 B2. The Board granted a joint motion to terminate the proceeding and treated the settlement agreement as confidential business information.
Detailed Summary
In IPR2025-00919, Mercedes‑Benz Group AG challenged U.S. Patent 10,259,465 B2 owned by Phelan Group, LLC. After the trial was instituted on November 21, 2025, the parties reached a settlement covering all related disputes, including those pending in the District Court. They filed a joint motion to terminate the inter partes review under 35 U.S.C. § 317(a) and to keep the settlement agreement confidential under 37 C.F.R. § 42.74(c). The Patent Trial and Appeal Board granted both requests, formally terminating the proceeding and ordering the settlement agreement to be treated as business‑confidential information.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Mercedes-Benz Group AG et al. vs Phelan Group, LLC is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Microsoft CorporationvsQomplx LLC
Microsoft has petitioned the PTAB to invalidate Qomplx’s multi-factor authentication patent, asserting that the claims are obvious over the Kirti patent and the Coffin textbook. The petition seeks institution of IPR on claims 1‑21, 23‑28, and 30.
CrowdStrike, Inc. et al.vsGoSecure, Inc.
GoSecure seeks Director Review to vacate the institution of two IPRs filed by CrowdStrike that challenge all 21 claims of U.S. Patent 9,954,872. The patent owner alleges the Board abused discretion by allowing duplicate petitions, misapplying claim ambiguity, and incorrectly construing “computer system.”
United Services Automobile AssociationvsAuto Telematics Ltd.
Auto Telematics Ltd. has filed a Request for Director Review challenging the PTAB’s institution of an IPR against its vehicle‑telematics patent, arguing the Board misinterpreted claim language and ignored discretionary denial grounds.
SAMSUNG ELECTRONICS CO., LTD. et al.vsOMNI MEDSCI, INC.
The PTAB held that Samsung’s challenge to Omni MedSci’s wearable physiological monitoring patent succeeded on 12 of the 23 claims, finding them obvious over prior‑art references such as Lisogurski, Carlson, Tran, Isaacson and Valencell‑093. The remaining claims were not shown unpatentable.
Zepp Health CorporationvsUniversity of Connecticut
Zepp Health has filed an IPR petition seeking to invalidate all 75 claims of U.S. Patent 10,278,647, arguing they are obvious over a 2015 academic paper on wrist‑type photoplethysmography. The petition also argues that the Board should not exercise discretionary denial.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.